Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Our AI ranks Biomerica Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Biomerica Inc is a small-cap company with a market capitalization of $9M. It ranks number 13 by market capitalization among the 17 In Vitro & In Vivo Diagnostic Substances issuers in our coverage with a current forecast. Its ROE of -141.9% is the lowest of the 11 peers that report one. Its Gross Margin of 12.1% is the lowest of the 9 peers that report one.
For BMRA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 27.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -8.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, BMRA included.
Follow BMRA free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the In Vitro & In Vivo Diagnostic Substances peers listed below that report each metric.
| Metric | BMRA | Rank |
|---|---|---|
| Market Cap | $9M | 13/17 |
| P/B Ratio | 2.33x | 6/12 |
| EPS | $-0.81 | – |
| Book Value/Share | $0.79 | – |
| Metric | BMRA | Rank |
|---|---|---|
| ROE | -141.9% | 11/11 |
| ROA | -64.2% | 11/13 |
| ROIC | -95.8% | 12/12 |
| Gross Margin | 12.1% | 9/9 |
| Operating Margin | -112.7% | 8/14 |
| Net Margin | -116.4% | 8/12 |
| EBT Margin | -86.3% | 8/14 |
| Tax Rate | -0.6% | – |
| Metric | BMRA | Rank |
|---|---|---|
| Current Ratio | 1.91x | 11/16 |
| Quick Ratio | 1.33x | 7/10 |
| D/E Ratio | 1.21x | 2/12 |
| Financial Leverage | 2.21x | 2/12 |
| Interest Coverage | -7344.2x | 14/14 |
| Working Capital | $3M | 13/16 |
| Metric | BMRA | Rank |
|---|---|---|
| Operating Cash Flow | -$3M | 6/16 |
| Metric | BMRA | Rank |
|---|---|---|
| Inventory Turnover | 2.6x | 8/10 |
| Days Inventory | 139 days | 3/10 |
| Payables Period | 127 days | 3/10 |
| Metric | BMRA | Rank |
|---|---|---|
| Operating Income | -$5M | 4/15 |
| Net Income | -$5M | 4/13 |
| R&D Expense | $790K | 15/16 |
| SG&A Expense | $5M | 12/12 |
| Cost of Goods Sold | $4M | 8/10 |
| Metric | BMRA | Rank |
|---|---|---|
| Shares Outstanding | 5M | – |
| Total Current Assets | $5M | 67.0% of assets |
| Cash & Short-term Investments | $3M | 33.8% of assets |
| Accounts Receivable | $900K | 11.1% of assets |
| Inventory | $2M | 20.2% of assets |
| Total Liabilities | $4M | 54.8% of assets |
| Short-term Debt | $1M | 16.6% of assets |
Companies classified under the same SEC industry code as Biomerica Inc (In Vitro & In Vivo Diagnostic Substances): 17 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| BMRA Biomerica Inc | ▲ | $9M |
| IDXX Idexx Laboratories Inc /De | ▼ | $44.15B |
| LNTH Lantheus Holdings, Inc. | ▼ | $6.51B |
| NEOG Neogen Corp | ▲ | $2.58B |
| CLDX Celldex Therapeutics, Inc. | ▲ | $2.16B |
| NTLA Intellia Therapeutics, Inc. | ▲ | $1.60B |
| QDEL Quidelortho Corp | ▲ | $885M |
| ACHV Achieve Life Sciences, Inc. | ▲ | $657M |
| MYGN Myriad Genetics Inc | ▲ | $381M |
| TKNO Alpha Teknova, Inc. | ▲ | $380M |
| IMDX Insight Molecular Diagnostics Inc. | ▲ | $98M |
| ICCC Immucell Corp /De/ | ▼ | $98M |
| AWHL Aspira Women's Health Inc. | ▲ | $11M |
| TRIB Trinity Biotech Plc | ▶ | $7M |
| CDIO Cardio Diagnostics Holdings, Inc. | ▲ | $5M |
| QCLS Q/C Technologies, Inc. | ▼ | $4M |
| VNRX Volitionrx Ltd | ▶ | $2M |
Biomerica, Inc. announced that the American Medical Association's CPT editorial panel has granted a Proprietary Laboratory Analysis (PLA) code for its inFoods® IBS test, which personalizes the ...
IRVINE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) ("Biomerica"), a global provider of advanced medical products, today announced that it will implement a 1-for-8 ...
BIOMERICA, INC. announced that on October 12, 2026, David Moatazedi, a member of the Board of Directors of Biomerica, Inc., communicated to the Board that he has determined not to stand ...
Our AI ranks Biomerica Inc outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For BMRA, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 27.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -8.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Biomerica Inc forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
17 issuers in our coverage, BMRA included, share the SEC industry code In Vitro & In Vivo Diagnostic Substances. The largest are: Idexx Laboratories Inc /De (IDXX), Lantheus Holdings, Inc. (LNTH), Neogen Corp (NEOG), Celldex Therapeutics, Inc. (CLDX), Intellia Therapeutics, Inc. (NTLA), Quidelortho Corp (QDEL).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.